Rochester, NY -- (SBWIRE) -- 12/05/2013 -- Shares of Puma Biotechnology (NYSE:PBYI) gapped up Thursday morning 30%. The stock has continued its run and is currently up over 50%.
This comes on the heels of positive results from the Phase II clinical trial of Puma's investigational drug PB272 (neratinib).
The odd thing is this positive news came out Wednesday morning and the stock ended up closing down yesterday. Why the delayed reaction? I don’t know. But the fact is currently Puma’s price is soaring.
Puma Biotechnology (NYSE:PBYI) will probably get a lot of new attention over the next few days and smart traders know the more new people looking at a stock the better the odds of tradeable price swings. This is especially true for over the counter stocks where investor awareness campaigns are the primary market driver. These campaigns generate a buzz and an influx of new interest that can send a stock price soaring. WhisperfromWallStreet specializes in identifying otc companies undergoing awareness campaigns and alerting our readers before the market opens putting them in position to profit. Click this link to sign up for our free newsletter.
WhisperfromWallStreet has been teaching investors how to trade OTC stocks since 2005. We clearly explain the market dynamics behind most major moves in the OTC markets and provide readers with time tested, easy to follow strategies they can use to stay ahead of the pack.
WhisperfromWallStreet.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WhisperfromWallStreet.com website, for complete risks and disclosures.
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)